KPRX Kiora Pharma Total Asset Value of Company

KPRX (kiorapharma.com) - company brandmark

Kiora Pharmaceuticals (KPRX) is implementing automated data analysis systems for retinal pathologies and robotic compound screening. The business relies on the development of ophthalmological agents in the US and strategic collaboration with Western clinics, with total assets amounting to 27.87. This price action visualized on the GURU.Markets platform complements information regarding the development of innovative photoswitches to combat blindness.

KPRX (Kiora Pharmaceuticals, Inc.) Company Total Assets history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company kiorapharma.com (KPRX)

- stock quotes and analyst forecast:
Share Price Kiora Pharmaceuticals, Inc.|KPRX - Price Target Chart
- market capitalization data:
Market Valuation Kiora Pharmaceuticals|KPRX - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Kiora Pharmaceuticals|KPRX - Book Capitalization|Market Capitalization to Book Value Ratio kiorapharma.com|KPRX - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Kiora Pharmaceuticals|KPRX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Kiora Pharmaceuticals, Inc.|KPRX - Company Aggregate Debts|Debts to Book Capitalization Kiora Pharmaceuticals|KPRX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Kiora Pharmaceuticals|Immediate Liquidity kiorapharma.com
- net income and valuation multiples indicators:
KPRX - Net Income
Fundamental valuation:Kiora Pharmaceuticals
Manufactured products of Kiora Pharmaceuticals Inc.

The stable operation of ophthalmology laboratories and equipment modernization at Kiora Pharmaceuticals (KPRX) are directly capitalized into total assets, which are reverse-calculated here via ROA to determine the company's total resource value. This metric measures the aggregate asset base and liabilities, allowing investors to use the total asset value to assess the risk of overpaying for an overheated business when buying at historical peaks.

Key competitors

Total Business Assets ALC|Aggregate Company Assets Bausch + Lomb|Glaukos Corp - Total Asset Value of Company|Company Total Assets APLS|BLTE (Belite Bio Inc) - Aggregate Asset Value|Company Total Assets OCUL (Ocular Therapeutix)|Company Total Assets harrowinc.com HROW|VRDN - Aggregate Company Assets|Aggregate Asset Value LENZ (LENZ Therapeutics Inc)|Oculis (OCS) - Aggregate Company Assets|Cumulative Company Assets EyePoint Corp|KOD (Kodiak Sciences Inc.) - Company Total Assets|Company Total Assets Aldeyra|Cumulative Company Assets KALA (KALA BIO, Inc.)|IRD (opusgtx.com) - Aggregate Asset Value|Company Total Assets OKYO (OKYO Pharma)|Adverum Biotechnologies Inc. (ADVM) - Company Assets|OTLK: Cumulative Company Assets|Company Assets clearsidebio.com|NBY: Company Total Assets|Company Assets Alimera Sciences, Inc. (ALIM)|Aggregate Company Assets Eyenovia Inc.|Guardion Health (GHSI) - Company Total Asset Base|Aggregate Company Assets Ocuphire Pharma, Inc. (OCUP)|Company Total Assets opthea.com (OPT)